Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Northwest Biotherapeutics (NWBO) over the last 15 years, with Q3 2025 value amounting to $1.5 million.

  • Northwest Biotherapeutics' Shares Outstanding (Diluted Average) rose 1855.71% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 1855.71%. This contributed to the annual value of $1.2 million for FY2024, which is 1099.42% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Shares Outstanding (Diluted Average) stood at $1.5 million for Q3 2025, which was up 1855.71% from $1.4 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Shares Outstanding (Diluted Average) ranged from a high of $1.5 million in Q3 2025 and a low of $834605.0 during Q1 2021
  • For the 5-year period, Northwest Biotherapeutics' Shares Outstanding (Diluted Average) averaged around $1.1 million, with its median value being $1.1 million (2023).
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first skyrocketed by 6616.27% in 2021, then tumbled by 1338.13% in 2022.
  • Northwest Biotherapeutics' Shares Outstanding (Diluted Average) (Quarter) stood at $1.0 million in 2021, then rose by 0.79% to $1.0 million in 2022, then rose by 10.17% to $1.1 million in 2023, then rose by 10.99% to $1.2 million in 2024, then grew by 20.11% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.4 million for Q2 2025, and $1.4 million during Q1 2025.